CSL Behring snaps up a close­ly-held biotech part­ner and its IL-6 drug — for trans­plant re­jec­tion

Hav­ing close­ly watched and fund­ed a Cana­di­an biotech part­ner’s IL-6 drug for two and a half years, CSL Behring is snap­ping it all up. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.